232 related articles for article (PubMed ID: 25011585)
1. Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer.
O'Leary PC; Terrile M; Bajor M; Gaj P; Hennessy BT; Mills GB; Zagozdzon A; O'Connor DP; Brennan DJ; Connor K; Li J; Gonzalez-Angulo AM; Sun HD; Pu JX; Pontén F; Uhlén M; Jirström K; Nowis DA; Crown JP; Zagozdzon R; Gallagher WM
Breast Cancer Res; 2014 Jul; 16(4):R79. PubMed ID: 25011585
[TBL] [Abstract][Full Text] [Related]
2. Selective association of peroxiredoxin 1 with genomic DNA and COX-2 upstream promoter elements in estrogen receptor negative breast cancer cells.
Wang X; He S; Sun JM; Delcuve GP; Davie JR
Mol Biol Cell; 2010 Sep; 21(17):2987-95. PubMed ID: 20631257
[TBL] [Abstract][Full Text] [Related]
3. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
4. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
5. Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents.
Bajor M; Zych AO; Graczyk-Jarzynka A; Muchowicz A; Firczuk M; Trzeciak L; Gaj P; Domagala A; Siernicka M; Zagozdzon A; Siedlecki P; Kniotek M; O'Leary PC; Golab J; Zagozdzon R
Br J Cancer; 2018 Oct; 119(7):873-884. PubMed ID: 30287919
[TBL] [Abstract][Full Text] [Related]
6. Peroxiredoxin I maintains luteal function by regulating unfolded protein response.
Park HJ; Lee DG; Seong JB; Lee HS; Kwon OS; Kang BS; Park JW; Lee SR; Lee DS
Reprod Biol Endocrinol; 2018 Aug; 16(1):79. PubMed ID: 30111318
[TBL] [Abstract][Full Text] [Related]
7. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.
Légaré S; Cavallone L; Mamo A; Chabot C; Sirois I; Magliocco A; Klimowicz A; Tonin PN; Buchanan M; Keilty D; Hassan S; Laperrière D; Mader S; Aleynikova O; Basik M
Cancer Res; 2015 Oct; 75(20):4351-63. PubMed ID: 26297734
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
[TBL] [Abstract][Full Text] [Related]
10. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells.
Caruso JA; Campana R; Wei C; Su CH; Hanks AM; Bornmann WG; Keyomarsi K
Cell Cycle; 2014; 13(16):2587-99. PubMed ID: 25486199
[TBL] [Abstract][Full Text] [Related]
11. Peroxiredoxin-1 Tyr194 phosphorylation regulates LOX-dependent extracellular matrix remodelling in breast cancer.
Attaran S; Skoko JJ; Hopkins BL; Wright MK; Wood LE; Asan A; Woo HA; Feinberg A; Neumann CA
Br J Cancer; 2021 Oct; 125(8):1146-1157. PubMed ID: 34389806
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.
Neubauer H; Clare SE; Wozny W; Schwall GP; Poznanovic S; Stegmann W; Vogel U; Sotlar K; Wallwiener D; Kurek R; Fehm T; Cahill MA
Breast Cancer Res; 2008; 10(5):R85. PubMed ID: 18922159
[TBL] [Abstract][Full Text] [Related]
13. Genistein modulates oxidative stress in breast cancer cell lines according to ERα/ERβ ratio: effects on mitochondrial functionality, sirtuins, uncoupling protein 2 and antioxidant enzymes.
Nadal-Serrano M; Pons DG; Sastre-Serra J; Blanquer-Rosselló Mdel M; Roca P; Oliver J
Int J Biochem Cell Biol; 2013 Sep; 45(9):2045-51. PubMed ID: 23871935
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer.
Guo QJ; Mills JN; Bandurraga SG; Nogueira LM; Mason NJ; Camp ER; Larue AC; Turner DP; Findlay VJ
Breast Cancer Res; 2013; 15(4):R70. PubMed ID: 23971998
[TBL] [Abstract][Full Text] [Related]
15. Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Kondo N; Kobayashi S; Fujii Y; Iwase H
Endocr Relat Cancer; 2008 Sep; 15(3):755-63. PubMed ID: 18550720
[TBL] [Abstract][Full Text] [Related]
16. ERRF is essential for Estrogen-Estrogen Receptor alpha signaling pathway in ER positive breast cancer cells.
Luo A; Zhang X
Biochem Biophys Res Commun; 2016 May; 474(2):400-405. PubMed ID: 27125460
[TBL] [Abstract][Full Text] [Related]
17. The peroxidase PRDX1 inhibits the activated phenotype in mammary fibroblasts through regulating c-Jun N-terminal kinases.
Jezierska-Drutel A; Attaran S; Hopkins BL; Skoko JJ; Rosenzweig SA; Neumann CA
BMC Cancer; 2019 Aug; 19(1):812. PubMed ID: 31419957
[TBL] [Abstract][Full Text] [Related]
18. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
O Leary PC; Penny SA; Dolan RT; Kelly CM; Madden SF; Rexhepaj E; Brennan DJ; McCann AH; Pontén F; Uhlén M; Zagozdzon R; Duffy MJ; Kell MR; Jirström K; Gallagher WM
BMC Cancer; 2013 Apr; 13():175. PubMed ID: 23547718
[TBL] [Abstract][Full Text] [Related]
19. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.
Ariazi EA; Brailoiu E; Yerrum S; Shupp HA; Slifker MJ; Cunliffe HE; Black MA; Donato AL; Arterburn JB; Oprea TI; Prossnitz ER; Dun NJ; Jordan VC
Cancer Res; 2010 Feb; 70(3):1184-94. PubMed ID: 20086172
[TBL] [Abstract][Full Text] [Related]
20. Differential expression and function of peroxiredoxin 1 and peroxiredoxin 6 in cancerous MCF-7 and noncancerous MCF-10A breast epithelial cells.
Goncalves K; Sullivan K; Phelan S
Cancer Invest; 2012 Jan; 30(1):38-47. PubMed ID: 22236188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
